Previous 10 | Next 10 |
ENGLEWOOD, CO / ACCESSWIRE / November 22, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced today that the C...
Ranked 94 th Fastest Growing Company in North America Ranked 21 st Fastest Growing Life Sciences Company ENGLEWOOD, CO / ACCESSWIRE / November 17, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company prov...
ENGLEWOOD, CO / ACCESSWIRE / November 16, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, announced the passing of Mic...
Aytu BioPharma, Inc. (AYTU) Q1 2023 Earnings Conference Call November 14, 2022, 04:30 PM ET Company Participants Roger Weiss - Lytham Partners Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Jennifer Kim - Cantor Fitzgerald Presen...
The following slide deck was published by Aytu BioPharma, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Aytu BioPharma, Inc. 2022 Q3 - Results - Earnings Call Presentation
Aytu BioScience press release ( NASDAQ: AYTU ): Q1 GAAP EPS of -$0.06. Revenue of $27.66M (+26.3% Y/Y). Consumer Health revenue during Q1 2023 was $9.0 million, an increase of 12% over the year ago quarter. Gross margins increased to 65% in Q1 2023 compared to 57% ...
Record Quarterly Net Revenue of $27.7 Million Driven by 34% Growth in Rx Segment Positive Adjusted EBITDA for the Quarter of $1.4 Million Leadership Changes Implemented to Focus on Commercial Operations Company to Host Conference Call Today at 4:30pm ET ENGLEWOOD, CO / ACC...
Aytu BioScience ( NASDAQ: AYTU ) is scheduled to announce Q1 earnings results on Monday, November 14th, after market close. The consensus EPS Estimate is -$0.18 (+83.5% Y/Y) and the consensus Revenue Estimate is $24.3M (+10.5% Y/Y). Over the last 3 months, EPS estimate...
ENGLEWOOD, CO / ACCESSWIRE / November 7, 2022 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, will report financial results...
Amendment of Secured Loan Agreement Extends Interest-Only Period to January 2024 Amendment Defers Over $3 Million in Principal Payments Beyond 2023 Note Matures in January 2025, with Additional Extensions of the Interest-Only Period Available, Subject to Achievement of Certain Mile...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...